Supercharging design of an anti-lysozyme Fab antibody to regulate ligand-dependent reversible aggregation
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Protein aggregation and liquid‒liquid phase separation (LLPS), as key physicochemical processes, orchestrate protein behavior and function, and engineering a protein surface charge offers a robust approach to modulate protein‒protein interactions and, consequently, aggregation and phase separation. Among protein surface engineering methods, supercharging leads to a drastic increase in the protein net charge by replacing surface residues with charged amino acid residues. Previous studies have reported that some physicochemical properties of proteins are improved by supercharging, and changing the surface charge is considered to affect intermolecular interactions. In this study, we designed a new supercharged antigen-binding fragment (Fab) antibody mutant and investigated its aggregation behavior. Upon examination of the physicochemical properties of the designed supercharged antibody, the thermal stability, structure, and ligand binding affinity of the antibody were retained despite having the same charge pairing of both the antibody and the antigen. Furthermore, we revealed that the antibody exhibited reversible ligand- and salt concentration-dependent aggregation. Our study demonstrated how supercharging can potentially modulate protein aggregation and LLPS. It is expected that this approach can be extended to other proteins, through which its applicability in various biological and biotechnological fields can be explored.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Supercharging design of an anti-lysozyme Fab antibody to regulate ligand-dependent reversible aggregation
- Date Crossref
- 25/04/2025
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
The University of Tokyo Medical Proteomics Laboratory pays non établi dans la noticeUniversité ou école supérieure
-
National Institute of Infectious Diseases pays non établi dans la noticeOrganisme public
-
School of Engineering Department of Bioengineering pays non établi dans la noticeUniversité ou école supérieure
-
Research Center for Drug and Vaccine Development pays non établi dans la noticeStructure de recherche
Medical Proteomics Laboratory — The University of Tokyo, National Institute of Infectious Diseases et Department of Bioengineering — School of Engineering, avec 1 autre affiliation.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.